Apellis Pharmaceuticals, Inc. (APLS)
Company Info
| ISIN | US03753U1060 |
|---|---|
| CUSIP | 03753U106 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $5.73B |
|---|---|
| EPS | -$4.45 |
| Revenue (TTM) | $396.59M |
| Gross Profit (TTM) | $69.79M |
| EBITDA (TTM) | -$515.34M |
| Year Range | $19.83 - $94.75 |
| Target Price | $82.13 |
| Short % | 10.05% |
| Short Ratio | 7.76 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: APLS vs. LNTH, APLS vs. ADI, APLS vs. ABBV, APLS vs. VRTX, APLS vs. VOO, APLS vs. ULTA, APLS vs. SPY
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Apellis Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Apellis Pharmaceuticals, Inc. had a return of -20.41% year-to-date (YTD) and -44.77% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -20.41% | 5.05% |
| 1 month | -13.99% | -4.27% |
| 6 months | 4.93% | 18.82% |
| 1 year | -44.77% | 21.22% |
| 5 years (annualized) | 20.36% | 11.38% |
| 10 years (annualized) | N/A | 10.42% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 5.73% | -2.09% | -5.15% | |||||||||
| 2023 | -9.88% | 27.92% | 10.71% | 11.12% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
Apellis Pharmaceuticals, Inc.(APLS)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Apellis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Apellis Pharmaceuticals, Inc. was 74.65%, occurring on Aug 7, 2023. The portfolio has not yet recovered.
The current Apellis Pharmaceuticals, Inc. drawdown is 48.94%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -74.65% | Jun 14, 2023 | 37 | Aug 7, 2023 | — | — | — |
| -61.77% | Apr 17, 2018 | 134 | Oct 24, 2018 | 216 | Sep 5, 2019 | 350 |
| -59.6% | Feb 11, 2020 | 25 | Mar 17, 2020 | 174 | Nov 20, 2020 | 199 |
| -55.99% | Jul 6, 2021 | 83 | Oct 29, 2021 | 357 | Apr 3, 2023 | 440 |
| -43.83% | Jan 5, 2018 | 25 | Feb 9, 2018 | 22 | Mar 14, 2018 | 47 |
Volatility
Volatility Chart
The current Apellis Pharmaceuticals, Inc. volatility is 15.67%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |